Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04896697 · ClinicalTrials.gov registry record · Phase 1
Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumor, sponsored by Xilio Development.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 136
- Enrollment target
- 19
- Study locations
NCT04896697: Recruiting Phase 1 study of Advanced Solid Tumor, sponsored by Xilio Development.
NCT04896697 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by Xilio Development. The registered enrollment target is 136 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (29% lower). The trial reports 19 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04896697, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by Xilio Development.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 136 participants
- Enrollment target
- 19
- Study locations
Study Summary
This is a first-in-human, Phase 1/2, multicenter, open-label study designed to evaluate the safety and tolerability of vilastobart (XTX101) as monotherapy and vilastobart (XTX101) and atezolizumab combination therapy in patients with advanced solid tumors.
Conditions Studied
Interventions
- DRUG Atezolizumab
- DRUG vilastobart (XTX101)
Study Locations (19)
California
- City of Hope - Duarte
- California Cancer Associates for Research and Excellence, cCARE - Encinitas
- City of Hope-Lennar - Irvine
- USC/Norris Comprehensive Cancer Center - Los Angeles
- California Cancer Associates for Research and Excellence, cCARE - San Marcos
- UCLA Hematology/Oncology- Santa Monica - Santa Monica
- City of Hope-Upland - Upland
Texas
- Next Oncology - Austin
- Mary Crowley Cancer Research - Dallas
- Tranquil Clinical Research - Webster
Florida
- Mayo Clinic Hospital - Jacksonville
- Sarah Cannon Research Institute at Florida Cancer Specialists - Orlando
North Carolina
- Duke University Medical Center - Durham
- Carolina BioOncology Institute - Huntersville
Arizona
- Mayo Clinic Hospital - Phoenix
Massachusetts
- Massachusetts General Hospital - Boston
Minnesota
- Mayo Clinic Hospital - Rochester
Pennsylvania
- University of Pittsburgh Medical Center- Hillman Cancer Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2021-09-13 |
| Est. Completion | 2026-03-30 |
| Phase | Phase 1 |
What NCT04896697 shows while recruiting
NCT04896697 is an interventional study that assigns participants to a tested intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (29% lower).
The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Atezolizumab is the first listed.
NCT04896697 lists 19 locations in 9 states (California, Texas, Florida).
Frequently Asked Questions
What is clinical trial NCT04896697 about?
NCT04896697 is a clinical study titled "Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors". This is a first-in-human, Phase 1/2, multicenter, open-label study designed to evaluate the safety and tolerability of vilastobart (XTX101) as monotherapy and vilastobart (XTX101) and atezolizumab combination therapy in patients with advanced solid tumors.
What is the current status of trial NCT04896697?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 136 participants. The study started on 2021-09-13. Estimated completion is 2026-03-30.
What conditions does trial NCT04896697 study?
This clinical trial studies the following conditions: Advanced Solid Tumor.
What interventions are being tested in trial NCT04896697?
The interventions under investigation include: Atezolizumab (DRUG), vilastobart (XTX101) (DRUG).
Who is sponsoring clinical trial NCT04896697?
This trial is sponsored by Xilio Development, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04896697 being conducted?
This trial has 19 study locations across Arizona, California, Florida, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04896697's enrollment target sits among peer trials
136 97th of 189 higher than 93 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01555892 · 136 participants · Phase 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- NCT03216525 · 136 participants · Phase 3
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
- NCT04476901 · 136 participants · Phase 2
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
- NCT04603898 · 136 participants · NA
Oxalate Formation From Ascorbic Acid
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI